PSA testing remains the only biomarker for prostate cancer detection and monitoring, but its specificity and sensitivity are limited, often leading to misdiagnosis as prostatitis or prostate stones (Benchikh El Fegoun and Villers, 2007). Here, KLK3 is linked to urogenital neoplasm.